Literature DB >> 18209996

[Humanes herpesvirus 8 (HHV-8) and Kaposi sarcoma].

C Lebbé1.   

Abstract

The Kaposi sarcoma-associated herpes virus (KSHV) or human herpesvirus 8 (HHV-8) is a gamma-herpesvirus (Rhadinovirus) present in all clinical cases of Kaposi sarcoma (KS). HHV-8 can be transmitted by blood and blood products, as well as in saliva during mother-child transfer. Sexual transmission is also possible although not conclusively proven. Actually the goal of treating KS is to reduce symptoms and, not to produce complete tumor remission. In patients with HIV- and posttransplant-associated KS; an improved immune status is essential. In addition, specific topical or systemic approaches are available. Therapeutic strategies to treat HHV-8 infection, in order to prevent the development of KS are currently investigated.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18209996     DOI： 10.1007/s00105-007-1445-3

Source DB:  PubMed          Journal:  Hautarzt        ISSN： 0017-8470            Impact factor:   0.751


  78 in total

1.  Human herpesvirus 8 latent-state gene expression and apoptosis in Kaposi's sarcoma lesions.

Authors:  G S Hayward
Journal:  J Natl Cancer Inst       Date:  1999-10-20       Impact factor: 13.506

Review 2.  Cell-homologous genes in the Kaposi's sarcoma-associated rhadinovirus human herpesvirus 8: determinants of its pathogenicity?

Authors:  F Neipel; J C Albrecht; B Fleckenstein
Journal:  J Virol       Date:  1997-06       Impact factor: 5.103

Review 3.  Targeting human herpesvirus-8 for treatment of Kaposi's sarcoma and primary effusion lymphoma.

Authors:  Carmen Manuela Klass; Margaret K Offermann
Journal:  Curr Opin Oncol       Date:  2005-09       Impact factor: 3.645

4.  Use of the ganciclovir implant for the treatment of cytomegalovirus retinitis in the era of potent antiretroviral therapy: recommendations of the International AIDS Society-USA panel.

Authors:  D F Martin; J P Dunn; J L Davis; J S Duker; R E Engstrom; D N Friedberg; G J Jaffe; B D Kuppermann; M A Polis; R J Whitley; R A Wolitz; C A Benson
Journal:  Am J Ophthalmol       Date:  1999-03       Impact factor: 5.258

5.  Sensitivity of Kaposi's sarcoma-associated herpesvirus replication to antiviral drugs. Implications for potential therapy.

Authors:  D H Kedes; D Ganem
Journal:  J Clin Invest       Date:  1997-05-01       Impact factor: 14.808

6.  The restricted cellular host range of human herpesvirus 8.

Authors:  D J Blackbourn; E Lennette; B Klencke; A Moses; B Chandran; M Weinstein; R G Glogau; M H Witte; D L Way; T Kutzkey; B Herndier; J A Levy
Journal:  AIDS       Date:  2000-06-16       Impact factor: 4.177

7.  Ugandan Kaposi's sarcoma-associated herpesvirus phylogeny: evidence for cross-ethnic transmission of viral subtypes.

Authors:  Henry Kajumbula; Robert G Wallace; Jian-Chao Zong; Joseph Hokello; Noah Sussman; Simon Simms; Robert F Rockwell; Robert Pozos; Gary S Hayward; William Boto
Journal:  Intervirology       Date:  2006       Impact factor: 1.763

8.  The TSC2/mTOR pathway drives endothelial cell transformation induced by the Kaposi's sarcoma-associated herpesvirus G protein-coupled receptor.

Authors:  Akrit Sodhi; Risa Chaisuparat; Jiadi Hu; Amanda K Ramsdell; Brendan D Manning; Edward A Sausville; Earl T Sawai; Alfredo Molinolo; J Silvio Gutkind; Silvia Montaner
Journal:  Cancer Cell       Date:  2006-08       Impact factor: 31.743

9.  Trends in cancer risk among people with AIDS in the United States 1980-2002.

Authors:  Eric A Engels; Ruth M Pfeiffer; James J Goedert; Phillip Virgo; Timothy S McNeel; Steven M Scoppa; Robert J Biggar
Journal:  AIDS       Date:  2006-08-01       Impact factor: 4.177

10.  Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells.

Authors:  C Boshoff; T F Schulz; M M Kennedy; A K Graham; C Fisher; A Thomas; J O McGee; R A Weiss; J J O'Leary
Journal:  Nat Med       Date:  1995-12       Impact factor: 53.440
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.